Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19.
Adult
Betacoronavirus
/ immunology
Biomarkers
/ metabolism
Blood Coagulation Disorders
/ immunology
Blood Platelets
/ metabolism
COVID-19
Case-Control Studies
Coronavirus Infections
/ complications
Female
Follow-Up Studies
Humans
Male
Middle Aged
Monocytes
/ metabolism
P-Selectin
/ metabolism
Pandemics
Platelet Activation
Pneumonia, Viral
/ complications
Prognosis
Prospective Studies
SARS-CoV-2
Survival Rate
Thromboplastin
/ metabolism
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
10 09 2020
10 09 2020
Historique:
received:
26
05
2020
accepted:
10
07
2020
pubmed:
18
7
2020
medline:
6
10
2020
entrez:
18
7
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent pathogen responsible for the coronavirus disease 2019 (COVID-19). Since its emergence, the novel coronavirus has rapidly achieved pandemic proportions causing remarkably increased morbidity and mortality around the world. A hypercoagulability state has been reported as a major pathologic event in COVID-19, and thromboembolic complications listed among life-threatening complications of the disease. Platelets are chief effector cells of hemostasis and pathological thrombosis. However, the participation of platelets in the pathogenesis of COVID-19 remains elusive. This report demonstrates that increased platelet activation and platelet-monocyte aggregate formation are observed in severe COVID-19 patients, but not in patients presenting mild COVID-19 syndrome. In addition, exposure to plasma from severe COVID-19 patients increased the activation of control platelets ex vivo. In our cohort of COVID-19 patients admitted to the intensive care unit, platelet-monocyte interaction was strongly associated with tissue factor (TF) expression by the monocytes. Platelet activation and monocyte TF expression were associated with markers of coagulation exacerbation as fibrinogen and D-dimers, and were increased in patients requiring invasive mechanical ventilation or patients who evolved with in-hospital mortality. Finally, platelets from severe COVID-19 patients were able to induce TF expression ex vivo in monocytes from healthy volunteers, a phenomenon that was inhibited by platelet P-selectin neutralization or integrin αIIb/β3 blocking with the aggregation inhibitor abciximab. Altogether, these data shed light on new pathological mechanisms involving platelet activation and platelet-dependent monocyte TF expression, which were associated with COVID-19 severity and mortality.
Identifiants
pubmed: 32678428
pii: S0006-4971(20)61728-1
doi: 10.1182/blood.2020007252
pmc: PMC7483437
doi:
Substances chimiques
Biomarkers
0
P-Selectin
0
SELP protein, human
0
Thromboplastin
9035-58-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1330-1341Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 by The American Society of Hematology.
Références
J Immunol. 2018 Jan 1;200(1):295-304
pubmed: 29167233
Blood. 2017 Oct 5;130(14):1607-1619
pubmed: 28794070
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Nat Commun. 2019 Jun 3;10(1):2402
pubmed: 31160588
Sci Transl Med. 2017 Aug 30;9(405):
pubmed: 28855397
Blood. 2015 Feb 12;125(7):1146-58
pubmed: 25538043
BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
J Thromb Haemost. 2020 Jun;18(6):1517-1519
pubmed: 32294295
Crit Care Med. 2012 Dec;40(12):3246-50
pubmed: 22971587
Am J Respir Cell Mol Biol. 2018 Jul;59(1):18-35
pubmed: 29553813
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Semin Thromb Hemost. 2019 Nov;45(8):802-809
pubmed: 31622994
J Thromb Haemost. 2008 Jun;6(6):986-94
pubmed: 18363812
Blood. 2014 May 1;123(18):2768-76
pubmed: 24366358
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Exp Med. 2006 Oct 30;203(11):2433-40
pubmed: 17060476
Sci Rep. 2019 Sep 16;9(1):13397
pubmed: 31527604
Eur Respir J. 2009 Nov;34(5):1148-58
pubmed: 19541719
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Br J Haematol. 2020 Jul;190(1):e29-e33
pubmed: 32420607
Front Immunol. 2019 Sep 13;10:2204
pubmed: 31572400
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
J Clin Invest. 1996 Mar 15;97(6):1525-34
pubmed: 8617886
Sci Rep. 2018 Oct 9;8(1):14999
pubmed: 30301959
Circ Res. 2018 Jan 19;122(2):337-351
pubmed: 29348254
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Thromb Res. 2010 Oct;126(4):e327-33
pubmed: 20451956
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5556-E5565
pubmed: 29793936
J Am Coll Cardiol. 2018 Jan 2;71(1):53-65
pubmed: 29301628
J Thromb Haemost. 2020 Jun;18(6):1469-1472
pubmed: 32302435
Thromb Haemost. 2013 Apr;109(4):684-95
pubmed: 23348831
Lancet Infect Dis. 2020 Jul;20(7):770-772
pubmed: 32502433
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Nat Rev Immunol. 2011 Apr;11(4):264-74
pubmed: 21436837
Sci Rep. 2019 May 8;9(1):7096
pubmed: 31068600
Ann N Y Acad Sci. 2010 Oct;1207:11-7
pubmed: 20955420
Nat Commun. 2019 Apr 16;10(1):1780
pubmed: 30992428
Infection. 2005 Aug;33(4):257-63
pubmed: 16091896
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Nat Med. 2007 Apr;13(4):463-9
pubmed: 17384648
FASEB J. 2003 Mar;17(3):476-8
pubmed: 12514112
Blood Adv. 2020 May 12;4(9):2018-2031
pubmed: 32396616
J Immunol. 2014 Aug 15;193(4):1864-72
pubmed: 25015827
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Blood. 2013 Nov 14;122(20):3405-14
pubmed: 24009231
J Immunol. 2015 Jun 15;194(12):5579-87
pubmed: 26048965
Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2322-8
pubmed: 11031222
J Thromb Haemost. 2011 Apr;9(4):748-58
pubmed: 21255247
Cell. 1989 Oct 20;59(2):305-12
pubmed: 2478294
Front Med (Lausanne). 2018 Apr 30;5:121
pubmed: 29761104
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):340-6
pubmed: 22156911
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8767-71
pubmed: 7522321
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
Blood. 2016 Aug 11;128(6):753-62
pubmed: 27354721